Tecentriq (atezolizumab): risk of severe cutaneous adverse reactions (SCARs)

Manufacturers warn that SCARs, including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Patients should be monitored for severe skin reactions. In case a SCAR is suspected, treatment should be withheld and patients should be referred to a specialist.

Source:

Hoffmann-La Roche Ltd